TME Pharma NV (XPAR:ALTME) Debt-to-Equity : -3.97 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV Debt-to-Equity?

TME Pharma NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.17 Mil. TME Pharma NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. TME Pharma NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-0.29 Mil. TME Pharma NV's debt to equity for the quarter that ended in Dec. 2023 was -3.97.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TME Pharma NV's Debt-to-Equity or its related term are showing as below:

XPAR:ALTME' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.97 Med: -0.06 Max: 0.54
Current: -3.97

During the past 10 years, the highest Debt-to-Equity Ratio of TME Pharma NV was 0.54. The lowest was -3.97. And the median was -0.06.

XPAR:ALTME's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs XPAR:ALTME: -3.97

TME Pharma NV Debt-to-Equity Historical Data

The historical data trend for TME Pharma NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Debt-to-Equity Chart

TME Pharma NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.06

0.08

0.54

-3.21

-3.97

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial													0.54	-	-3.21	-14.29	-3.97

Competitive Comparison of TME Pharma NV's Debt-to-Equity

For the Biotechnology subindustry, TME Pharma NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Debt-to-Equity falls into.

TME Pharma NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TME Pharma NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.166	+	0)	/	-0.294
	=	-3.97

TME Pharma NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.166	+	0)	/	-0.294
	=	-3.97

TME Pharma NV (XPAR:ALTME) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TME Pharma NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV (XPAR:ALTME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines